ArticleFrontiers in oncology2026
The role of the preoperative HALP score in predicting pathological T and N categories in colon cancer: a single-center retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The HALP score is an easily accessible immunonutritional biomarker that may reflect systemic inflammation and nutritional status. This study aimed to evaluate the association of the preoperative HALP score with pathological T (pT) and N (pN) categories in patients with colon cancer. In addition, the performance of the HALP score in distinguishing between early (pT1-2) and advanced (pT3-4) T categories was investigated. Methods: This single-center retrospective study included 100 patients who underwent elective surgery for nonmetastatic colon cancer between December 2020 and December 2025. Patients who received neoadjuvant treatment, had M1 disease, or underwent emergency surgery because of bleeding or obstruction were excluded. The HALP score was calculated using hemoglobin, albumin, lymphocyte, and platelet values obtained from peripheral venous blood within one week before surgery. Discriminative performance was evaluated using ROC analysis, and cut-off values were determined using the Youden index. Results: The patients were evaluated in three comparison groups: in Group 1, patients with pN0 disease were compared with those with pN+ disease; in Group 2, patients with pT1-2/pN0 disease were compared with all other patients; and in Group 3, patients with pT1-2 disease were compared with those with pT3-4 disease, irrespective of pN status. The discriminative performance of the HALP score was not significant in Group 1 (AUC = 0.53; 95% CI: 0.42-0.65; p = 0.568), whereas the AUC was 0.77 in Group 2 (95% CI: 0.64-0.89; p < 0.001) and 0.81 in Group 3 (95% CI: 0.71-0.92; p < 0.001). At the cut-off value of 55.37 determined for Groups 2 and 3, sensitivity was 55.0% and 60.0%, respectively, while specificity was 91.2% and 96.0%, respectively. These results demonstrated that Group 3 had statistically better diagnostic performance than Group 2. Conclusion: In colon cancer, the HALP score was able to distinguish between early (pT1-2) and advanced (pT3-4) T categories, irrespective of pN status. Our findings suggest that the HALP score may serve as an adjunctive biomarker that could contribute to preoperative risk assessment in patients with colon cancer. The study findings should be validated in larger, prospective, multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.